GHRP-2 Spray

The GHRP-2 molecular structure contains ester bond modification sites (e.g., {d-2Nal}-Trp ester bond), which nasal microbiome carboxyl esterases can specifically recognize and hydrolyze. Experiments demonstrated:

In vitro metabolism experiments: After 2-hour incubation in Staphylococcus aureus culture supernatant, the ester bond cleavage rate of GHRP-2 reached 32%, yielding two metabolic fragments: {d-2Nal} and Trp-{d-Phe}-Lys-NH₂. Enzyme kinetic analysis indicated the reaction follows the Michaelis-Menten equation, with a Km value of 0.85 mM and Vmax of 12.3 nmol/min/mg.

In vivo validation: The concentration of GHRP-2 ester bond hydrolysis products in nasal lavage fluid from chronic sinusitis patients was 2.8 times higher than in healthy volunteers, suggesting significantly elevated enzyme activity under pathological conditions.

The aldehyde group in GHRP-2's side chain may serve as a target for aldehyde dehydrogenase:

Oxidation Product Analysis: Under Moraxella catarrhalis catalysis, the aldehyde group oxidizes to a carboxyl group, increasing molecular polarity and reducing mucosal permeability. Animal studies showed that intranasal inoculation with strains exhibiting high aldehyde dehydrogenase activity reduced GHRP-2 cerebrospinal fluid concentrations by 27%.

Metabolite Disposition: Oxidation products may be rapidly cleared via nasal clearance systems (e.g., ciliary movement) or further metabolized by host enzymes into dicarboxylic acid derivatives, which are less readily absorbed.

If cyclic structures exist in the GHRP-2 molecule (as in certain synthetic analogues), epoxidases can catalyze their ring-opening:

Ring-opening efficiency: Bacillus enzymes exhibit 95% efficiency in cleaving epoxyethane structures, yielding ortho-diol derivatives. The cleaved products may alter molecular conformation, potentially affecting binding affinity to the ghrelin receptor.

Stereoselectivity: Epoxidases exhibit strict stereoselectivity, catalyzing ring-opening only for epoxides with specific configurations, which may influence the biological activity of metabolites.

Proteases secreted by the nasal microbiome degrade the peptide bonds of GHRP-2:

N-terminal degradation: Aminopeptidases preferentially act on N-terminal amino acids, accelerating GHRP-2 N-terminal degradation by 2.3-fold and generating the {d-Ala}-{d-2Nal}-Trp tripeptide fragment.

C-terminal degradation: Carboxypeptidase acts on C-terminal amino acids, reducing molecular weight and biological activity. Experiments show that binding affinity of C-terminal degradation products to receptors decreases by 60%.

Broad-spectrum esterase inhibitors: Adding 0.1% betadine (betamethasone) enhances GHRP-2 stability in the nasal cavity by 60%, though caution is warranted regarding its potential inhibition of host esterases.

Selective Aldehyde Dehydrogenase Inhibitors: Dithiocarbamate compounds specifically inhibit Moraxella aldehyde dehydrogenase activity, prolonging GHRP-2 duration while reducing oxidative product formation.

Protease Inhibitors: Camostat mesylate inhibits multiple bacterial proteases, protecting GHRP-2 from peptide bond cleavage and preserving its biological activity.

Probiotic supplementation: Inoculation with Bacillus pseudodiphtheriae competitively inhibits Staphylococcus aureus growth, reduces overall carboxylesterase activity, and produces beneficial metabolites like SCFAs to modulate the local immune environment.

Phage therapy: Developing phages specific to enzyme-producing drug-resistant bacteria enables precise elimination of highly active strains without disrupting normal microbiota. For example, phage K targeting Staphylococcus aureus reduces its esterase activity by 70%.

Synthetic Biology Modification: Utilizing the CRISPR-Cas system to knockout enzyme-producing genes or introducing genes expressing degradative enzyme inhibitors to construct a "metabolically friendly" microbiome.

Nanoencapsulation Technology: Encapsulating GHRP-2 within poly(lactic-co-glycolic acid) (PLGA) nanoparticles reduces enzyme exposure area, boosting bioavailability to 45%. Surface modification with polyethylene glycol (PEG) prolongs intranasal retention time.

pH-Responsive Gels: Developed smart formulations stable below pH 6.0 and releasing drugs above pH 6.5 to bypass peak microbial enzyme activity. For example, chitosan-sodium tripolyphosphate gels remain gel-like below pH 6.2 and dissolve above pH 6.5, enabling precise controlled release.

Enzyme immobilization technology: Immobilizing esterases onto the surface of nasal delivery devices pre-degrades sensitive ester bonds in GHRP-2, reducing its metabolic loss within the nasal cavity.